---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-011971"
form_type: "8-K"
ticker: "CCCC"
cik: "0001662579"
company_name: "C4 Therapeutics, Inc."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:40:07.845566+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# C4 Therapeutics reports Q4 net loss $20.5M, cash $297M; cemsidomide Phase 2 trial dosed

## Summary
- Q4 revenue $11.0M, net loss $20.5M ($0.18/sh); full-year net loss $105.0M ($1.27/sh).
- Cash, equivalents and marketable securities $297.1M as of Dec 31, 2025; runway to end of 2028.
- First patient dosed in Phase 2 MOMENTUM trial of cemsidomide for multiple myeloma; designed for accelerated approval.
- Phase 1b trial of cemsidomide + elranatamab (Pfizer supply) to initiate Q2 2026; collaboration agreement signed Oct 2025.
- October 2025 raised $125M gross proceeds from underwritten offering; warrants could add $225M.

## SEC filing metadata
- accession: 0001628280-26-011971
- form_type: 8-K
- ticker: CCCC
- cik: 0001662579
- company_name: C4 Therapeutics, Inc.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662579/000162828026011971/0001628280-26-011971-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662579/000162828026011971/cccc-20260226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-011971
- JSON: https://secwatch.observer/filing/0001628280-26-011971.json
- Plain text: https://secwatch.observer/filing/0001628280-26-011971.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.